CS Paper Radar

Deep Learning for Automated Quantification of Tumor-Associated Macrophages from H&E-Stained Slides in Diffuse Large B-Cell Lymphoma

Anastasiia Studenikina, Svetlana Illarionova, Joaquim Carreras, Daniil Sulimov, Olga Filimonova, Dmitry Zvezdin, Arsenii Galimov, Ivan Tyukin, Rifat Hamoudi, Maxim Sharaev

eess.IV ·submitted 2026-08-19 10:08 UTC · v1

Abstract

While M2-polarized tumor-associated macrophages (TAMs) have been established as indicators of disease aggressiveness in diffuse large B-cell lymphoma (DLBCL), traditional CD163 immunohistochemistry (IHC) remains resource-intensive. This study aims to investigate the feasibility of using deep learning to quantify TAMs directly from standard hematoxylin and eosin-stained (HE) tissue sections. Using a curated dataset of 52 patients with DLBCL, with high-resolution HE images and IHC-validated annotations (1,713 TAM instances), five architectures were evaluated: U-Net, Swin-U-Net, Cerberus-U-Net3+, YOLOv11, and HoVer-Net. High CD163 TAM density (>20.04%) was associated with significantly reduced overall survival (HR 2.73; 95% CI:1.21-6.16; p=0.012) and progression-free survival (HR 2.88; 95% CI: 1.23-6.76; p=0.011). In multivariate Cox proportional hazards analysis adjusting for IPI, molecular subtype (GCB/non-GCB per Hans algorithm), EBV status, and age, CD163 TAM density showed a prognostic trend for overall survival (HR 3.24; 95% CI: 0.94-11.15; p=0.062) and progression-free survival (HR 2.41; 95% CI: 0.80-7.32; p=0.120). Among the evaluated models, the domain-specific Cerberus-U-Net3+ achieved the highest sensitivity (Recall 0.656), while the Transformer-based Swin-U-Net demonstrated superior segmentation fidelity (Precision 0.694, F1-score 0.633). Additionally, the survival analysis based on the predicted Swin-U-Net CD163 level revealed a 20.8% cutoff point for patients with high and low CD163 levels near IHC, as well as a downward trend in overall survival among patients with higher predicted CD163 values of 2.63 (95% CI: 0.85-8.33; p=0.083). These findings suggest that deep learning architectures using shifted-window self-attention show potential as a candidate surrogate for IHC that is scalable and cost-effective for prognostic assessment of TAMs in DLBCL.

Comment
17 pages, 5 figures, 7 tables

Closest papers

Nearest neighbours by meaning across the whole index.

Detail in Context: A Dual-Scale Machine Learning Framework for Mycosis Fungoides Detection

cs.CV ·2026-09-29 ·Mohamed Hazem, Tarek Waleed, Omar Khaled, Nada Omar, Mahmoud Raslan +6 more
similarity 0.65
Abstract

Mycosis fungoides (MF) is a rare form of cutaneous T-cell lymphoma that is often misdiagnosed in early stages due to its visual similarity to benign inflammatory dermatoses. Early and accurate diagnosis is critical for improving patient outcomes. In this paper, we propose a comprehensive diagnostic framework for automated MF detection that combines dual- scale histopathological image analysis with deep learning. To distinguish MF from other lymphoproliferative skin conditions, the proposed approach leverages a late-fusion ensemble of dual- magnification (10x and 20x) convolutional neural networks (CNNs), complemented by a random forest classifier trained on 16 clinical features. Experimental results on an expanded dataset of 6,267 images (4,306 MF; 1,961 Non-MF) across 463 patients demonstrate that strong detection performance is obtained by prioritizing higher-resolution cytological details (20x) within broader architectural context (10x). The image-based late-fusion model achieves an accuracy of 83.58% and a sensitivity of 89.13%, while the clinical random forest model achieves an accuracy of 96.6% and sensitivity of 93.8%, highlighting the po- tential of this multimodal framework as a robust clinical decision support system in dermatology. This framework addresses two distinct clinical objectives: an image-based dual-scale pipeline optimized for the early diagnostic screening of MF versus non- MF dermatoses, and a complementary clinical metadata model designed for the subsequent staging of confirmed MF cases (patch/plaque versus tumor)

0.11

Deep Learning for Cervical Cytology Screening: Methods, Algorithms, Challenges and Prospects

cs.CV ·2026-11-01 ·Jiang Yangbo, Zheng Nenggan
benchmark similarity 0.64
Abstract

Cervical cancer remains a leading cause of cancer death among women, with more than 90\% of deaths occurring in low- and middle-income countries, where cytology screening is constrained by a shortage of trained cytopathologists. Deep learning has made automated cytology screening increasingly feasible, but the literature is fragmented across cell, patch and whole-slide-image scales, task formulations and supervision regimes, hindering comparison and clinical translation. This Review synthesizes the deep learning literature for cervical cytology screening, organizing the field along three axes---data scale, functional task and supervision---and distinguishing two clinical roadmaps: whole-slide-image confidence aggregation and cell-level detection with Bethesda classification. We examine 16 publicly available or publicly documented cytology datasets alongside the CAISHI histopathology dataset, compare quantitative performance while exposing incomparable metrics and data leakage, and assess commercial systems, regulatory status, HPV-era screening pathways and low-resource deployment. Single-cell accuracy on Herlev and SIPaKMeD has plateaued, but this reflects benchmark saturation rather than clinical readiness; prospective and randomized evidence is emerging but remains limited. We consolidate the evidence into five challenge areas---data and benchmarks, architecture and label-efficient learning, trustworthy AI, clinical translation and health economics, and evaluation and reproducibility---and provide an evidence-to-agenda map and a deployment decision matrix. Progress now depends on multi-center benchmarks, externally validated label-efficient methods, calibrated and fair predictions, and pragmatic clinical trials rather than further gains on saturated single-cell benchmarks.

0.09

Comprehensive Benchmarking of Deep Learning Architectures for Lung Cancer Histopathology

cs.CV cs.AI ·2026-08-16 ·Hadi Hasan, Safaa Salman, Lama Sleem, Ralph Mouawad, Ali Chehab
benchmark similarity 0.62
Abstract · 8 pages

Lung cancer remains the leading cause of cancer-related mortality worldwide, while histopathological diagnosis is often affected by inter-observer variability and the substantial workload associated with manual slide examination. Although deep learning has shown considerable potential in computational pathology, comprehensive benchmarks that integrate tissue classification and region segmentation within a unified analytical framework remain limited. This study presents a two-stage deep learning framework for multi-class tissue classification and pixel-level histopathological region segmentation, accompanied by a systematic comparison of state-of-the-art architectures at each stage. For tissue classification, six models, a custom convolutional neural network, VGG16, DenseNet, MobileNetV3, a custom Vision Transformer, and YOLO11, are evaluated on a combined dataset of 39,000 images derived from LC25000 and LungHist700. The models distinguish between adenocarcinoma, squamous cell carcinoma, and normal lung tissue. YOLO11 achieves the best classification performance, with an accuracy of 98.38%, a five-fold cross-validation accuracy of 98.21 +/- 0.35%, and a macro F1-score of 0.98. For region segmentation, U-Net, ResNet-encoder U-Net, DeepLabV3+, and YOLO11-seg are evaluated using the GlaS gland segmentation benchmark. DeepLabV3+ obtains the highest Intersection over Union of 0.80 and a Dice score of 0.89, while YOLO11-seg achieves a comparable Intersection over Union of 0.79 using approximately 14x fewer parameters. The best-performing classification and segmentation models are subsequently integrated into an end-to-end framework, providing an accurate, computationally efficient, and reproducible baseline for automated histopathological image analysis.

0.40

HEmIF-Bench: Benchmarking H&E-to-mIF Models BeyondVirtual-StainFidelity

cs.CV ·2026-11-15 ·Fuxian Zhao, Hyokeun Park
benchmark similarity 0.61
Abstract · 11 pages, 3 figures, 2 tables

Hematoxylin and eosin (H&E)-to-multiplex immunofluorescence (mIF) generators predict spatial protein expression from routine histology, yet pixel-level marker reconstruction does not establish downstream utility. We present HEmIF-Bench, evaluating five frozen generators across eight datasets spanning molecular, cellular, tissue, and patient scales. HEmIF-Bench decouples internal encoder features from generated outputs, benchmarking both against the pathology foundation reference UNI2. Mirroring the clinical workflow where pathologists rely on mIF to define cell phenotypes, delineate tertiary lymphoid structures (TLSs) and germinal centers (GCs), and stratify patient risk, we evaluate external CD3 recovery, single-cell classification, dense nuclear segmentation, TLS/GC segmentation, and patient survival prediction. Across the benchmark, foundation-model-based MIPHEI-ViT leads among the generators, while non-foundation models show task-specific strengths. Comparing the two routes reveals that internal encoder features generally outperform generated outputs, and larger output marker panels do not guarantee stronger downstream utility across datasets. Moreover, neither internal encoder features nor generated outputs consistently surpass frozen UNI2. These findings show that pixel-level stain fidelity does not equate to downstream utility, and that generators trained at current paired-data scales have yet to surpass large-scale pure-H&E foundation models. With the expansion of paired translation cohorts and the advancement of foundation-based generative architectures, HEmIF-Bench establishes a definitive benchmark for tracking when H&E-to-mIF generation crosses the threshold to deliver genuine value beyond routine histology for tumor microenvironment analysis and precision oncology.

0.13

AI-based characterization of lymphoid structures and the tumor microenvironment reveals lower mature tertiary lymphoid structures, lymph-node follicles, and plasma cells after neoadjuvant therapy in lung squamous cell carcinoma

cs.CV q-bio.QM ·2026-11-09 ·Arne Schmidt, Justin Nieder, Cornelius Boehm, Julika Ribbat-Idel, Marius Teodorescu +22 more
similarity 0.61
Abstract

Mature, germinal centre-bearing tertiary lymphoid structures (TLS) and mature lymph node follicles (secondary lymphoid structures, SLS) sustain the plasma cell response that shapes outcome and immunotherapy benefit in lung cancer. How this loco-regional axis differs between neoadjuvant-treated and therapy-naive tumors is poorly defined. We analyzed H&E whole-slide images of resected tumors and paired proximal and distal lymph nodes from matched neoadjuvant-treated (neoLUSC, n=20) and therapy-naive (naivLUSC, n=20) lung squamous cell carcinoma (LUSC) patients. Aignostics Atlas H&E Tissue Analysis (HETA) models quantified cell densities per tissue compartment and cell-cell co-localization; a dedicated deep-learning model validated against pathologist annotations detected TLS and SLS and graded their maturity. Prognostic value was tested in an independent cohort (n=458; 46 treated). In neoLUSC tumors, stromal plasma cell density was 72% (p=0.004) and stromal lymphocyte density 48% (p=0.015) lower than in naivLUSC; macrophages and granulocytes did not differ significantly. Total and immature TLS did not differ, whereas mature TLS in the tumor (p=0.034) and mature SLS in the tumor-distal lymph node (p=0.003) were lower in neoLUSC patients. Peri-TLS plasma cell density correlated with tumor lymphocyte density in naivLUSC (rho=0.54, p=0.017) but not in neoLUSC tumors (rho=0.07). In the validation cohort, stromal plasma cell density (HR 0.69, p=0.011) and lymphocyte-plasma cell co-localization (HR 0.66, p=0.004) were associated with longer survival, and neoadjuvant status with shorter survival (HR 1.50, p=0.026). Neoadjuvant therapy is thus associated with fewer mature lymphoid structures and weaker coupling of the humoral compartment to the tumor rather than uniformly lower immune readouts. The stromal plasma cell/co-localization axis is a candidate prognostic biomarker.

0.31

Cross-Modal Contrastive Learning for the Retrieval of Immunotherapy-Associated Molecular Signatures from Histopathology

cs.LG cs.AIcs.IR ·2026-10-04 ·Sigrid Vila-Bagaria, Mar Teixidó, Miquel Piñol, Felip Vilardell, Robert Montal +1 more
published similarity 0.60
Abstract · Accepted to MICCAI 2026 CaPTion Workshop

Gastric Adenocarcinoma is a leading cause of cancer mortality. Although "Inflamed/Non-Inflamed" subtypes have been proposed to predict immunotherapy response, their identification relies on a costly 10-gene RNA signature. We propose a Cross-modal Contrastive Multiple Instance Learning (CCMIL) framework for cross-modal retrieval, imputing these molecular signatures directly from standard Hematoxylin & Eosin (H&E) slides. By leveraging a supervised contrastive objective, CCMIL aligns visual morphological patterns with molecular phenotypes into a shared latent space. This establishes an interpretable search-by-case retrieval engine, enabling pathologists to query a whole slide image to surface transcriptomically coherent neighbors and approximate RNA signatures without genomic sequencing at inference. Our results demonstrate that this retrieval-first approach captures the continuous phenotypic spectrum of tumor inflammation and yields clinically interpretable attention heatmaps. Furthermore, the learned representation also supports competitive downstream classification, providing a practical molecular pre-screening strategy.

0.26

CytoBERT: A Foundation Model for Cytometry Data

cs.LG ·2026-08-14 ·Syed Abdul Haseeb Qadri, Bjarne C. Hiller, Felix Blanke, Vanja Sophie Cangalovic, Kutalmış Coşkun +5 more
code/data similarity 0.59
Abstract

Cytometry measures the complex characteristics of single cells (e.g., counts and protein expression of immune cells) and is widely used across immunological research and clinical settings. However, cytometry data is highly heterogeneous and unstandardized due to experimental protocols and the choice of measured features. While machine learning methods hold the potential to gain deeper insights into cell biology, these challenges make them difficult to apply and transfer across studies. Recent advances in foundation models can alleviate these issues, but corresponding approaches are still scarce in this field. To address this, we provide CytoBERT, a publicly available, open-source, open-weight foundation model for single-cell cytometry data with variable marker panels. CytoBERT is pretrained in a self-supervised manner on a large-scale cytometry corpus (15 human datasets with heterogeneous marker panels and more than 50 million cells) curated through marker standardization, enabling it to learn transferable inter-marker relationships within cells. Fine-tuning CytoBERT for sample-level classification demonstrates that transfer learning across heterogeneous cytometry datasets is feasible, providing a starting point for scalable, generalizable cytometry analysis. Code is available at GitHub.

0.50

SCALE: Towards whole-slide counterfactual explanations in pathology

cs.CV ·2026-11-10 ·Weiyi Qin, Yingci Liu-Swetz, Shiwei Tan, Yi Wang, Mohammad Alexanderani +9 more
similarity 0.59
Abstract

Cancer diagnosis relies on histopathological evaluation, where tumor morphology guides disease classification and informs treatment decisions. Deep learning (DL) models excel at predicting diagnostic properties from histopathology images. Unlike typical medical images featuring small critical areas, histopathological images are textural, with relevant texture spanning the entire image; this makes it challenging to explain DL predictions by locating relevant image regions. Counterfactual explanations offer a promising alternative by asking "what changes in the image could have altered the model prediction." To achieve this, we propose SCALE, a framework for generating such counterfactual explanations for histopathological DL models. Across nine counterfactual directions spanning multiple cancer types, SCALE generates whole-slide counterfactual explanations that consistently shift predictions toward the intended target while maintaining biological feasibility. Blinded assessment by six board-certified pathologists showed higher morphological plausibility for SCALE (with a win rate of 91.7% over baselines) and promising counterfactual effectiveness (with a target consistency of 96.7%).

0.18